Phase III Trial of Durvalumab for Mesothelioma Underway
The U.S. Food and Drug Administration will be closely watching the latest, international phase III clinical trial for unresectable pleural mesothelioma involving the immunotherapy drug durvalumab. FDA approval may be coming soon. “It looks very promising,” Dr. Arkadiusz Dudek, of Regions Hospital Cancer Care Center in St. Paul, Minnesota, told The Mesothelioma Center at Asbestos.com. “The hope is to have the regimen approved by the FDA as front-line therapy. There is a real need today for more options with mesothelioma.” The goal of the randomized trial – officially known as DREAM3R &...
Source: Asbestos and Mesothelioma News - April 1, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Study: Which Mesothelioma Patients Will Immunotherapy Benefit?
This study also is designed to better understand the biological mechanisms affecting the immune system. The goal is to use both the cellular organization and molecular pathways to develop a test that can predict the response to the checkpoint inhibitor drugs. Upon completion, a clinical trial would follow, in which treatment would depend on the results of the individual’s test. “Within the next year or two, we’ll have a good idea of whether these components are working,” Burt said. The post Study: Which Mesothelioma Patients Will Immunotherapy Benefit? appeared first on Mesothelioma Center - Vital S...
Source: Asbestos and Mesothelioma News - February 23, 2021 Category: Environmental Health Authors: Amy Edel Source Type: news

FDA Fast-Tracks Mesothelioma Vaccine Development
The U.S. Food and Drug Administration has granted Fast-Track Designation this week to ONCOS-102, an immunotherapy vaccine that targets malignant mesothelioma and other hard-to-treat tumors. This designation is expected to expedite the regulatory approval process. The vaccine’s developer, Targovax, a small biotech company that focuses on oncolytic viruses, sees this as an early endorsement from the FDA. “Yes, this opens the door for us,” Dr. Magnus Jaderberg, chief medical officer of Targovax, told The Mesothelioma Center at Asbestos.com. “It validates what the FDA believes is a potentially promising...
Source: Asbestos and Mesothelioma News - February 19, 2021 Category: Environmental Health Authors: Amy Edel Source Type: news

Combo Immunotherapy in NSCLC: Not These Two Drugs Combo Immunotherapy in NSCLC: Not These Two Drugs
Pembrolizumab monotherapy remains a standard of care, after trial results show that adding ipilimumab conveys no benefits but incurs greater toxicity.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 10, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Opdivo Study Offers Hope to Relapsed Mesothelioma Patients
A recent study out of the United Kingdom finds patients with relapsed malignant mesothelioma can be treated effectively with single-agent nivolumab, safely improving overall and progression-free survival. Nivolumab, also known by the brand name Opdivo, is an immunotherapy drug already being used successfully with non-small cell lung cancer. It is the first drug to show a significant survival advantage for relapsed mesothelioma in a phase III clinical trial, according to principal investigator Dr. Dean Fennell, medical oncologist at the University of Leicester in England. “This is very encouraging news,” Fennell...
Source: Asbestos and Mesothelioma News - February 4, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Researchers: Mesothelioma Trials Need More Inclusive Criteria
Clinical trials for mesothelioma need more inclusive criteria to better reflect the patients being seen at major cancer treatment centers, according to a recent study conducted in Sydney, Australia. The study demonstrated a significant difference between those carefully selected for clinical trials and real-world patients with pleural mesothelioma. “A broader patient population more resembling real life would be able to access the novel treatment early,” Dr. Steven Kao, medical oncologist at Chris O’Brien Lifehouse hospital and one of the study authors, told The Mesothelioma Center at Asbestos.com. &ldquo...
Source: Asbestos and Mesothelioma News - February 2, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Lasting Benefit With Nivo Plus Ipi in Advanced Liver Cancer Lasting Benefit With Nivo Plus Ipi in Advanced Liver Cancer
Long-term follow-up data show a continued benefit in advanced hepatocellular carcinoma (HCC) with nivolumab and ipilimumab after disease progression on sorafenib in the Checkmate 040 trial.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 1, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Adding ipilimumab to pembrolizumab does not improve efficacy in patients with NSCLC
(International Association for the Study of Lung Cancer) Adding ipilimumab to pembrolizumab does not improve efficacy and is associated with greater toxicity than pembrolizumab alone as first-line therapy for metastatic non-small cell lung cancer (NSCLC) for patients with a PD-L1 tumor proportion score of greater than or equal to 50% and no targetable EGFR or ALK aberrations. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 29, 2021 Category: Cancer & Oncology Source Type: news

Statins May Give Boost to Mesothelioma Immunotherapy Drugs
This study, which included both patients with pleural mesothelioma and with advanced non-small cell lung cancer, found a potential synergy with the immunotherapy drugs. Opdivo and Keytruda, generically called nivolumab and pembrolizumab, respectively, are known as PD-1 inhibitors, drugs that restrict a protein from stopping immune response to cancer cells. “Statins may lead to prolonged antigen retention on cell membrane and strengthen antigen presentation to T cells, thus suggesting a potential synergy with PD-1 inhibitors,” the authors wrote. “The anti-tumor effect of statins might be attributed to an i...
Source: Asbestos and Mesothelioma News - January 7, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Top 10 Mesothelioma and Asbestos News Stories of 2020
Growing allegations of asbestos-contaminated talc in various consumer products, coupled with historic approval of a new treatment for pleural mesothelioma, made 2020 a year filled with both anxiety and hope. Johnson & Johnson stopped selling its iconic baby powder in May after being hit by thousands of lawsuits contending its talc-based product was causing various cancers, including ovarian cancer and malignant mesothelioma. The U.S. Food and Drug Administration approved the immunotherapy combination of Opdivo and Yervoy in October, the first new drug regimen approved for first-line treatment of unresectable disease in...
Source: Asbestos and Mesothelioma News - December 15, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Study: Immunotherapy Vaccine for Mesothelioma Still Promising
The ONCOS-102 immunotherapy vaccine continues its move toward future, first-line standard of care treatment for malignant pleural mesothelioma, based upon the latest study follow-up data. When combined with standard chemotherapy, the genetically modified adenovirus has produced a median overall survival of at least 18.2 months, according to results released in late November from the ongoing clinical trial. Median overall survival was more than four months better than the control group receiving chemotherapy alone in the randomized trial. ONCOS-102 is manufactured by Targovax, a small Scandinavian biotech company focused on...
Source: Asbestos and Mesothelioma News - December 3, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Hackensack University Medical Center cancer specialist demonstrates safety of novel agent
(Hackensack Meridian Health) The findings, published in the online edition of Clinical Cancer Research on Nov. 4, 2020, suggest that BMS-986178, an investigational OX40 agonist, has an acceptable safety profile in patients with advanced solid tumors, whether used as monotherapy or in combination with the checkpoint inhibitors nivolumab (Opdivo ® ) and/or ipilimumab (Yervoy ® ). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 30, 2020 Category: Cancer & Oncology Source Type: news

Rare angiosarcoma tumors respond well to immunotherapy combination
(SWOG) Researchers from SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute's (NCI) Division of Cancer Diagnosis and Treatment (DCTD), part of the National Institutes of Health, have shown that the immunotherapy combination of ipilimumab and nivolumab shrinks rare angiosarcoma tumors in 25 percent of all patients, with some having an even stronger response to the drug combination. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 13, 2020 Category: Cancer & Oncology Source Type: news

Drug Combo Approved for First - Line Treatment of Mesothelioma
Opdivo - Yervoy combination approved to treat adults with unresectable malignant pleural mesothelioma (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 6, 2020 Category: Cancer & Oncology Tags: Oncology, Pharmacy, FDA Approvals, Source Type: news

FDA Approves Opdivo, Yervoy Combination for Mesothelioma
The U.S. Food and Drug Administration has approved the immunotherapy combination of Opdivo and Yervoy for first-line treatment of unresectable malignant pleural mesothelioma. It was the first new drug regimen approved for mesothelioma in 16 years and only the second systemic therapy ever. The historic treatment approval for this cancer without a cure was the first since the FDA approved the chemotherapy combination of pemetrexed and cisplatin in 2004. “This marks the beginning of a new era for mesothelioma,” Dr. Bernardo Goulart, medical oncologist at Seattle Cancer Care Alliance, told The Mesothelioma Center a...
Source: Asbestos and Mesothelioma News - October 5, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

FDA Approves Opdivo, Yervoy Combination for Mesothelioma
The U.S. Food and Drug Administration has approved the immunotherapy combination of Opdivo and Yervoy for first-line treatment of unresectable malignant pleural mesothelioma. It was the first new drug regimen approved for mesothelioma in 16 years and only the second systemic therapy ever. The historic treatment approval for this cancer without a cure was the first since the FDA approved the chemotherapy combination of pemetrexed and cisplatin in 2004. “This marks the beginning of a new era for mesothelioma,” Dr. Bernardo Goulart, medical oncologist at Seattle Cancer Care Alliance, told The Mesothelioma Center a...
Source: Asbestos and Mesothelioma News - October 5, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

FDA OKs Combo Therapy for First-Line Mesothelioma Treatment FDA OKs Combo Therapy for First-Line Mesothelioma Treatment
Combination nivolumab and ipilimumab has now been approved as first-line treatment in mesothelioma and possibly a new standard of care.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 3, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Opdivo (nivolumab) + Yervoy (ipilimumab) as the First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma
PRINCETON, N.J.--(BUSINESS WIRE) October 2, 2020 -- Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) 360 mg every three weeks plus Yervoy (ipilimumab) 1 mg/kg every six weeks (injections for intravenous use) was approved by... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 2, 2020 Category: Drugs & Pharmacology Source Type: news

FDA approves nivolumab and ipilimumab for unresectable malignant pleural mesothelioma
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - October 2, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Mesothelioma Trial to Test Cancer Vaccine with Immunotherapy
A research team at Oslo University Hospital in Norway has opened a mesothelioma clinical trial using the novel UV1 cancer vaccine alongside a promising immunotherapy combination. UV1 is a peptide-based vaccine designed to induce a specific T-cell response and increase the effectiveness of the immunotherapy drugs. This is the first time UV1 will be studied with mesothelioma cancer, but it already has shown safety and signs of efficacy when used on malignant melanoma, prostate cancer and lung cancer in studies worldwide. It will be used with the immunotherapy combination of nivolumab and ipilimumab, also known by brand names...
Source: Asbestos and Mesothelioma News - September 14, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Combination immunotherapy benefits subset of patients with advanced prostate cancer
(University of Texas M. D. Anderson Cancer Center) esults from a Phase II trial led by researchers at MD Anderson Cancer Center suggest that a combination of ipilimumab (anti-CTLA-4) plus nivolumab (anti-PD-1) can generate durable responses in a subset of patients with advanced prostate cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 10, 2020 Category: Cancer & Oncology Source Type: news

Immunotherapy Combination Extends Mesothelioma Survival
Standard-of-care treatment for unresectable pleural mesothelioma cancer could be changing soon, sparked by a recently completed international study of a novel immunotherapy combination. Patients in the randomized mesothelioma clinical trial who were treated with ipilimumab (Yervoy) and nivolumab (Opdivo) had a median overall survival of 18.1 months, compared to 14.1 months for those receiving chemotherapy. The results of the mesothelioma trial, which was sponsored by Bristol Myers Squibb, were presented at the recent World Conference on Lung Cancer virtual meeting. Authors of the study said it was the first time an immuno...
Source: Asbestos and Mesothelioma News - August 11, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Chemo-Free Management of Mesothelioma on Horizon Chemo-Free Management of Mesothelioma on Horizon
Combination immunotherapy with nivolumab and ipilimumab could replace chemotherapy for patients with treatment-naive mesothelioma, suggest new phase 3 trial data.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 11, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Nivolumab Plus Ipilimumab or Pembrolizumab Most Cost-Effective for Newly Diagnosed Advanced Melanoma Nivolumab Plus Ipilimumab or Pembrolizumab Most Cost-Effective for Newly Diagnosed Advanced Melanoma
BRAF and MEK inhibitors might be used in a second-line setting after BRAF pathogenic variant is confirmed.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - August 4, 2020 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

Merck, Targovax Team Up for New Mesothelioma Clinical Trial
Standard-of-care treatment for malignant mesothelioma could change significantly, depending upon the results of an upcoming clinical trial of two immunotherapy agents used in combination with chemotherapy. The mesothelioma clinical trial will involve pembrolizumab, also known by the brand name Keytruda, and its synergy with ONCOS-102, a lesser-known, genetically modified adenovirus. Individually, both have shown modest efficacy for mesothelioma patients when used with chemotherapy. Together, there is potential for a much greater impact in significantly extending patient survival. The clinical trial is a partnership between...
Source: Asbestos and Mesothelioma News - July 22, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Frontline Nivolumab/Ipilimumab with Limited Chemo Derives OS Benefit in NSCLC
Overall survival (OS) benefit derived from frontline treatment with nivolumab plus ipilimumab combined with 2 cycles of platinum-doublet chemotherapy in patients with metastatic or recurrent non-small cell lung cancer was further improved after at least 12 months of follow-up. (Source: CancerNetwork)
Source: CancerNetwork - May 31, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

Nivolumab/Ipilimumab Combo Yields Durable Efficacy in Advanced NSCLC
Frontline treatment with nivolumab plus ipilimumab induced durable and long-term efficacy, compared with chemotherapy, in patients with advanced non-small cell lung cancer, regardless of PD-L1 expression. (Source: CancerNetwork)
Source: CancerNetwork - May 30, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

FDA approves nivolumab plus ipilimumab and chemotherapy for first-line treatment of metastatic NSCLC
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 27, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Approves Nivolumab Plus Ipilimumab with Chemotherapy for NSCLC
The FDA approved the use of nivolumab plus ipilimumab given with 2 cycles of platinum-doublet chemotherapy as a first-line treatment for adult patients with metastatic or recurrent non-small cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - May 27, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

FDA Approves Opdivo (nivolumab) + Yervoy (ipilimumab) Combined with Limited Chemotherapy as First-Line Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer
PRINCETON, N.J.--(BUSINESS WIRE) May 26, 2020 --Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) 360 mg plus Yervoy (ipilimumab) 1 mg/kg (injections for intravenous use) given with two cycles of platinum-doublet chemotherapy... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 26, 2020 Category: Drugs & Pharmacology Source Type: news

U.S. Food and Drug Administration Approves Opdivo (nivolumab) + Yervoy (ipilimumab) Combined with Limited Chemotherapy as First-Line Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer
PRINCETON, N.J.--(BUSINESS WIRE) May 26, 2020 --Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) 360 mg plus Yervoy (ipilimumab) 1 mg/kg (injections for intravenous use) given with two cycles of platinum-doublet chemotherapy... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 26, 2020 Category: Drugs & Pharmacology Source Type: news

FDA Approves Chemo-Free Combo for Lung Cancer FDA Approves Chemo-Free Combo for Lung Cancer
The combination of nivolumab plus ipilimumab is now approved as first-line treatment for patients with metastatic non-small-cell lung cancer.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 16, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

FDA approves nivolumab plus ipilimumab for first-line mNSCLC (PD-L1 tumor expression ≥1%)
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 15, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Approves Combination of Nivolumab Plus Ipilimumab for mNSCLC
The FDA approved the combination of nivolumab plus ipilimumab as a first-line treatment for patients with metastatic non-small cell lung cancer whose tumors express PD-L1 ( ≥1%), as determined by an FDA-approved test. (Source: CancerNetwork)
Source: CancerNetwork - May 15, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

U.S. Food and Drug Administration Approves Opdivo (nivolumab) + Yervoy (ipilimumab) as First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 ≥1%
PRINCETON, N.J.--(BUSINESS WIRE) May 15, 2020 --Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) 3 mg/kg plus Yervoy (ipilimumab) 1 mg/kg (injections for intravenous use) was approved by the U.S. Food and Drug Administration... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 15, 2020 Category: Drugs & Pharmacology Source Type: news

Mesothelioma Drug Combination Continues to Show Promise
Pharmaceutical giant Bristol Myers Squibb continues to tout its immunotherapy combination of Opdivo and Yervoy for first-line treatment of patients with pleural mesothelioma cancer. Bristol Myers Squibb recently announced that overall survival “significantly improved” when the combination was measured against standard chemotherapy in a randomized, phase III clinical trial of previously untreated mesothelioma patients. Its announcement was based on a pre-specific interim analysis conducted by the Data Monitoring Committee, a clinical study organization independent of Bristol Myers Squibb. The study is being cond...
Source: Asbestos and Mesothelioma News - May 4, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

CheckMate-743 Trial of Nivolumab, Ipilimumab Meets Primary Endpoint in Mesothelioma Trial
The trial evaluating nivolumab in combination with ipilimumab in previously untreated malignant pleural mesothelioma met its primary endpoint of overall survival. (Source: CancerNetwork)
Source: CancerNetwork - April 21, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

FDA Grants Priority Review to Nivolumab Plus Ipilimumab to Treat NSCLC
Bristol Myers Squibb recently announced that the FDA granted priority review to nivolumab plus ipilimumab in combination with chemotherapy as a first-line treatment for metastatic NSCLC. (Source: CancerNetwork)
Source: CancerNetwork - April 8, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news

Patients of Metastatic Prostate Cancer Could Benefit from Immunotherapy Treatment
A recent study found that a group of patients with metastatic castration-resistant prostate cancer responded positively to treatment with ipilimumab, prolonging survival after treatment in the “favorable” cohort. (Source: CancerNetwork)
Source: CancerNetwork - April 7, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news

FDA Approves Immunotherapy Combo for Liver Cancer FDA Approves Immunotherapy Combo for Liver Cancer
Nivolumab and ipilimumab together produce a response rate double that of nivolumab alone in advanced hepatocellular carcinoma.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 11, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA grants accelerated approval to nivolumab and ipilimumab combination for hepatocellular carcinoma
Hematology / Oncology Approvals (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 11, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

U.S. Food and Drug Administration approves Opdivo ® (nivolumab) + Yervoy® (ipilimumab) for patients with hepatocellular carcinoma (HCC) previously treated with sorafenib
Bristol Myers Squibb Company (NYSE: BMY) today announced that Opdivo (nivolumab) 1 mg/kg plus Yervoy (ipilimumab) 3 mg/kg (injections for intravenous use) was approved by the U.S. Food and Drug Administration (FDA) to treat hepatocellular carcinoma (HCC) in patients who have been previously treated with sorafenib.1,2 Approval for this indication has been granted under accelerated approval based on (Source: World Pharma News)
Source: World Pharma News - March 11, 2020 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news

FDA Approves Nivolumab-Ipilimumab Combo for Hepatocellular Carcinoma
The FDA approved the combination use of nivolumab plus ipilimumab for the treatment of patients with HCC who have been previously treated with sorafenib. (Source: CancerNetwork)
Source: CancerNetwork - March 11, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

Some Rare Neuroendocrine Tumors May Respond to Ipilimumab Plus Nivolumab Some Rare Neuroendocrine Tumors May Respond to Ipilimumab Plus Nivolumab
Patients with fast-growing non-pancreatic neuroendocrine tumors may respond to combination therapy with ipilimumab plus nivolumab, according to findings within the Dual Anti-CTLA-4& Anti-PD-1 blockade in Rare Tumors (DART) trial.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - March 5, 2020 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

Pre-operative immunotherapy triggers encouraging response in oral cancers
(American Society for Radiation Oncology) A new clinical trial suggests that immunotherapy given before other treatments for oral cavity cancers can elicit an immune response that shrinks tumors, which could provide long-term benefit for patients. In the randomized trial, two neoadjuvant doses of nivolumab given with or without ipilimumab led to complete or partial tumor shrinkage in most cases and did not delay any patients from continuing on to standard treatment. Findings will be presented at the 2020 Multidisciplinary Head and Neck Cancers Symposium. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 27, 2020 Category: Cancer & Oncology Source Type: news

Mesothelioma Clinical Trial Involves Immunotherapy Before Surgery
Three of the country’s leading cancer centers have opened a collaborative clinical trial that potentially could change surgical treatment of mesothelioma. Researchers will measure the safety and efficacy of using two different immunotherapy drug regimens — Opdivo (nivolumab) and Yervoy (ipilimumab) — beginning 42 days before surgery. The hope is that at least one will make surgical resection more effective. Sidney Kimmel Cancer Center at Johns Hopkins University, MD Anderson Cancer Center at the University of Texas and Greenebaum Cancer Center at the University of Maryland are working together to enroll a...
Source: Asbestos and Mesothelioma News - February 24, 2020 Category: Environmental Health Authors: Matt Mauney Source Type: news

U.S. Food and Drug Administration accepts for Priority Review Bristol-Myers Squibb's application for Opdivo (nivolumab) plus Yervoy (ipilimumab) in first-line non-small cell lung cancer
Bristol-Myers Squibb Company (NYSE: BMY) announced the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the first-line treatment of patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. (Source: World Pharma News)
Source: World Pharma News - January 17, 2020 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news

FDA Grants Priority Review to Frontline Nivolumab-Ipilimumab Combo for NSCLC
The FDA accepted and granted priority review to the supplemental biologics license application for nivolumab in combination with ipilimumab for the first-line treatment of patients with metastatic or recurrent non-small cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - January 15, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

Immunotherapy is safe following chemoradiotherapy for women with node-positive cervical cancer
(NRG Oncology) Results from the NRG Oncology phase I clinical trial NRG-GOG 9929 show that utilizing the immunotherapy drug ipilimumab after chemoradiotherapy (CRT) is tolerated in the curative treatment of women with lymph node-positive cervical cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 27, 2019 Category: Cancer & Oncology Source Type: news